Page 7 - Inaugural HKU Urology Congress program book (high resolution) 2026 0723
P. 7

COURSE PROGRAM                              INTERNATIONAL FACULTY



 1 August 2026 (Saturday)


 1/F., Daniel & Mayce Yu Administration Wing
 LKS Faculty of Medicine, The University of Hong Kong
 21 Sassoon Road, Pokfulam, Hong Kong  Woon-Chau Tsang   Consultant
                                                         Department of Urology
 Time  Topic  Speaker
                                                         National University Hospital
 9:00 - 9:30  Registration                               Singapore

 9:30 - 9:45  Welcoming Remarks and Photo-taking  Edward Che-Hung Leong

                      Hai-Feng Wang                      Director & Full Professor
 9:45 - 10:05  Moderator: Po-Chor Tam
                                                         Department of Urology
 Starting Focal Therapy for Prostate Cancer:   Steve Wai-Hee Chan  Shanghai Eastern Hospital Affiliated to
 Experience Sharing
                                                         Tongji University
 10:05 - 10:25  Moderator: Chiu-Fung Tsang               Shanghai

 Transperineal Irreversible Electroporation (IRE) Focal   Wai-Kit Ma
 Ablation for Prostate Cancer: Where Are We at 2026?

 10:25 - 11:10  Break at the Exhibition Area

 11:10 - 11:40  Moderator: Donald Chi-Ho Ip

 Semi Live Surgery and Discussion  John Shung-Lai Leung

 11:40 - 12:10  Moderator: Henry Hong-Yin Lie

 From Precision Biopsy to Targeted Therapy with a   Woon-Chau Tsang
 Robotic Fusion Platform

 12:10 - 13:20  Hands-on Experience at the Exhibition Area

 13:20 - 14:20  Lunch


 14:20 - 14:35  Moderator: Sau-Loi Ng

 Pre-and Post-Procedure Nursing Care of Patients   Pui-Yu Wong
 Receiving Fusion Prostate Biopsy

 14:35 - 14:55  Moderator: Wayne Lam

 The CUHK Focal Therapy Program - Lessons Learnt  Peter Ka-Fung Chiu
 and the Way Ahead

 14:55 - 15:25  Moderator: Simon Hoi-Lung Wong

 Transperineal IRE for Prostate Cancer: A Multicentre   Hai-Feng Wang
 Mainland China Experience and Oncological Outcomes

 15:25 - 15:30  Closing Remarks



 4                                                          5
   2   3   4   5   6   7   8   9   10   11   12